Page last updated: 2024-11-10

ici 199441

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ICI 199441: structure given in first source; RN refers to (monohydrochloride, (S))-isomer; a potent & selective kappa agonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3082718
CHEMBL ID38576
CHEBI ID93291
SCHEMBL ID7640991
MeSH IDM0163032
PubMed CID3082717
SCHEMBL ID7647023
MeSH IDM0163032

Synonyms (60)

Synonym
BRD-K73290745-003-01-8
NCGC00024784-01 ,
tocris-0778
NCGC00024784-02
CHEMBL38576 ,
ici-199441
2-(3,4-dichlorophenyl)-n-methyl-n-[(1s)-1-phenyl-2-pyrrolidin-1-ylethyl]acetamide
(s)-2-(3,4-dichlorophenyl)-n-methyl-n-(1-phenyl-2-(pyrrolidin-1-yl)ethyl)acetamide
bdbm50007344
(s)-2-(3,4-dichloro-phenyl)-n-methyl-n-(1-phenyl-2-pyrrolidin-1-yl-ethyl)-acetamide(ici 199441)
2-(3,4-dichloro-phenyl)-n-methyl-n-((s)-1-phenyl-2-pyrrolidin-1-yl-ethyl)-acetamide
ici-199,441
SCHEMBL7640991
CHEBI:93291
benzeneacetamide, 3,4-dichloro-n-methyl-n-((1s)-1-phenyl-2-(1-pyrrolidinyl)ethyl)-
3,4-dichloro-n-methyl-n-((1s)-1-phenyl-2-(1-pyrrolidinyl)ethyl)benzeneacetamide
benzeneacetamide, 3,4-dichloro-n-methyl-n-(1-phenyl-2-(1-pyrrolidinyl)ethyl)-, (s)-
q5r50x7l6m ,
116508-24-8
gr-199,441
unii-q5r50x7l6m
gr-199441
Q12745435
2-(3,4-dichlorophenyl)-n-methyl-n-[(1s)-1-phenyl-2-(1-pyrrolidinyl)ethyl]acetamide
159531-32-5
ici199441
gtpl11691
ligand 1 [pmid: 8893842]
DTXSID101029523
(s)-3,4-dichloro-n-methyl-n-(1-phenyl-2-(1-pyrrolidinyl)ethyl)benzeneacetamide monohydrochloride
ct5e310ajl ,
unii-ct5e310ajl
benzeneacetamide, 3,4-dichloro-n-methyl-n-(1-phenyl-2-(1-pyrrolidinyl)ethyl)-, monohydrochloride, (s)-
ici 199441
ici 199,441
n-(2-(n-methyl-3,4-dichlorophenylacetamido)-2-phenylethyl)pyrrolidine
115199-84-3
ici-199,441 hydrochloride
SCHEMBL7647023
ici 199,441 hydrochloride
2-(3,4-dichlorophenyl)-n-methyl-n-[(1s)-1-phenyl-2-(1-pyrrolidinyl)ethyl]acetamide hydrochloride
AKOS024458644
J-003264
2-(3,4-dichlorophenyl)-n-methyl-n-[1-phenyl-2-(pyrrolidin-1-yl)ethyl]acetamide--hydrogen chloride (1/1)
DTXSID60921646
EX-A7087
(s)-2-(3,4-dichlorophenyl)-n-methyl-n-(1-phenyl-2-(pyrrolidin-1-yl)ethyl)acetamide hydrochloride
115199-84-3 (hcl)
ici-199441 hcl
2-(3,4-dichlorophenyl)-n-methyl-n-[(1s)-1-phenyl-2-pyrrolidin-1-ylethyl]acetamide;hydrochloride
MS-27563
benzeneacetamide, 3,4-dichloro-n-methyl-n-((1s)-1-phenyl-2-(1-pyrrolidinyl)ethyl)-, hydrochloride (1:1)
136378-38-6
benzeneacetamide, 3,4-dichloro-n-methyl-n-((1s)-1-phenyl-2-(1-pyrrolidinyl)ethyl)-, monohydrochloride
ici-199441 hydrochloride
benzeneacetamide, 3,4-dichloro-n-methyl-n-[(1s)-1-phenyl-2-(1-pyrrolidinyl)ethyl]-, hydrochloride (1:1)
2-(3,4-dichlorophenyl)-n-methyl-n-[(1s)-1-phenyl-2-(1-
pyrrolidinyl)ethyl]acetamide hydrochloride
CS-0020983
HY-101205

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"Lead compound 1 was successfully redesigned to provide compounds with improved pharmacokinetic profiles for this series of human urotensin-II antagonists."( Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles.
Aiyar, NV; Behm, DJ; Carballo, LH; Dodson, JW; Douglas, SA; Dowdell, SE; Erhard, K; Evans, CA; Fries, HE; Girard, GR; Goodman, KB; Hilfiker, MA; Jin, J; McAtee, JJ; Nagilla, R; Neeb, MJ; Roethke, TJ; Sehon, CA; Sha, D; Shi, D; Viet, AQ; Wang, F; Wang, GZ; Wang, N; Wang, Y; Xu, X; Yuan, CC; Zhang, D, 2008
)
0.35

Bioavailability

ExcerptReferenceRelevance
" Replacement of the 2-pyrrolidinylmethyl-3-phenyl-piperidine core of 1 with a substituted N-methyl-2-(1-pyrrolidinyl)ethanamine core as in compound 7 resulted in compounds with improved oral bioavailability in rats."( Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles.
Aiyar, NV; Behm, DJ; Carballo, LH; Dodson, JW; Douglas, SA; Dowdell, SE; Erhard, K; Evans, CA; Fries, HE; Girard, GR; Goodman, KB; Hilfiker, MA; Jin, J; McAtee, JJ; Nagilla, R; Neeb, MJ; Roethke, TJ; Sehon, CA; Sha, D; Shi, D; Viet, AQ; Wang, F; Wang, GZ; Wang, N; Wang, Y; Xu, X; Yuan, CC; Zhang, D, 2008
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
acetamidesCompounds with the general formula RNHC(=O)CH3.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (44)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
USP1 protein, partialHomo sapiens (human)Potency10.00000.031637.5844354.8130AID504865
TDP1 proteinHomo sapiens (human)Potency18.39830.000811.382244.6684AID686978; AID686979
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency31.62280.001318.074339.8107AID926; AID938
67.9K proteinVaccinia virusPotency16.80370.00018.4406100.0000AID720579; AID720580
glucocerebrosidaseHomo sapiens (human)Potency25.11890.01268.156944.6684AID2101
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency1.41250.035520.977089.1251AID504332
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency0.01260.00207.533739.8107AID891
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency15.84890.316212.443531.6228AID902
cytochrome P450 2C19 precursorHomo sapiens (human)Potency0.31620.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency0.10000.00636.904339.8107AID883
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency89.12510.354828.065989.1251AID504847
mitogen-activated protein kinase 1Homo sapiens (human)Potency39.81070.039816.784239.8107AID995
survival motor neuron protein isoform dHomo sapiens (human)Potency28.18380.125912.234435.4813AID1458
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency6.30960.031610.279239.8107AID884; AID885
lethal factor (plasmid)Bacillus anthracis str. A2012Potency6.30960.020010.786931.6228AID912
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency12.58930.316212.765731.6228AID881
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency5.09570.00638.235039.8107AID881; AID883
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency6.30961.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)Ki0.00000.00000.12345.5000AID239438
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)0.02600.00002.015110.0000AID241920
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)Ki0.00000.00000.10825.5000AID239438
Kappa-type opioid receptorMus musculus (house mouse)IC50 (µMol)0.00250.00131.538010.0000AID148306
Mu-type opioid receptorHomo sapiens (human)Ki0.05300.00000.419710.0000AID238871; AID331199
Delta-type opioid receptorHomo sapiens (human)Ki0.02400.00000.59789.9300AID238911; AID331200
Kappa-type opioid receptorCavia porcellus (domestic guinea pig)IC50 (µMol)0.00360.00030.71237.0700AID147956; AID148567; AID148686
Kappa-type opioid receptorHomo sapiens (human)Ki0.00000.00000.362410.0000AID148022; AID238876; AID239438; AID331198
Mu-type opioid receptorCavia porcellus (domestic guinea pig)Ki0.00010.00000.27869.0000AID148022
Urotensin-2 receptorHomo sapiens (human)Ki4.00000.00080.67724.0000AID407192
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Kappa-type opioid receptorHomo sapiens (human)EC50 (µMol)0.00030.00000.22448.9900AID240265; AID331201; AID407193
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Kappa-type opioid receptorMus musculus (house mouse)Ke0.01780.00000.32251.5510AID224414
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (91)

Processvia Protein(s)Taxonomy
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMu-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
sensory perceptionMu-type opioid receptorHomo sapiens (human)
negative regulation of cell population proliferationMu-type opioid receptorHomo sapiens (human)
sensory perception of painMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayMu-type opioid receptorHomo sapiens (human)
behavioral response to ethanolMu-type opioid receptorHomo sapiens (human)
positive regulation of neurogenesisMu-type opioid receptorHomo sapiens (human)
negative regulation of Wnt protein secretionMu-type opioid receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeMu-type opioid receptorHomo sapiens (human)
calcium ion transmembrane transportMu-type opioid receptorHomo sapiens (human)
cellular response to morphineMu-type opioid receptorHomo sapiens (human)
regulation of cellular response to stressMu-type opioid receptorHomo sapiens (human)
regulation of NMDA receptor activityMu-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayMu-type opioid receptorHomo sapiens (human)
immune responseDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerDelta-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
adult locomotory behaviorDelta-type opioid receptorHomo sapiens (human)
negative regulation of gene expressionDelta-type opioid receptorHomo sapiens (human)
negative regulation of protein-containing complex assemblyDelta-type opioid receptorHomo sapiens (human)
positive regulation of CREB transcription factor activityDelta-type opioid receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationDelta-type opioid receptorHomo sapiens (human)
response to nicotineDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayDelta-type opioid receptorHomo sapiens (human)
eating behaviorDelta-type opioid receptorHomo sapiens (human)
regulation of mitochondrial membrane potentialDelta-type opioid receptorHomo sapiens (human)
regulation of calcium ion transportDelta-type opioid receptorHomo sapiens (human)
cellular response to growth factor stimulusDelta-type opioid receptorHomo sapiens (human)
cellular response to hypoxiaDelta-type opioid receptorHomo sapiens (human)
cellular response to toxic substanceDelta-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayDelta-type opioid receptorHomo sapiens (human)
immune responseKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
chemical synaptic transmissionKappa-type opioid receptorHomo sapiens (human)
sensory perceptionKappa-type opioid receptorHomo sapiens (human)
locomotory behaviorKappa-type opioid receptorHomo sapiens (human)
sensory perception of painKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
response to insulinKappa-type opioid receptorHomo sapiens (human)
positive regulation of dopamine secretionKappa-type opioid receptorHomo sapiens (human)
negative regulation of luteinizing hormone secretionKappa-type opioid receptorHomo sapiens (human)
response to nicotineKappa-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
maternal behaviorKappa-type opioid receptorHomo sapiens (human)
eating behaviorKappa-type opioid receptorHomo sapiens (human)
response to estrogenKappa-type opioid receptorHomo sapiens (human)
estrous cycleKappa-type opioid receptorHomo sapiens (human)
response to ethanolKappa-type opioid receptorHomo sapiens (human)
regulation of saliva secretionKappa-type opioid receptorHomo sapiens (human)
behavioral response to cocaineKappa-type opioid receptorHomo sapiens (human)
sensory perception of temperature stimulusKappa-type opioid receptorHomo sapiens (human)
defense response to virusKappa-type opioid receptorHomo sapiens (human)
cellular response to lipopolysaccharideKappa-type opioid receptorHomo sapiens (human)
cellular response to glucose stimulusKappa-type opioid receptorHomo sapiens (human)
positive regulation of p38MAPK cascadeKappa-type opioid receptorHomo sapiens (human)
positive regulation of potassium ion transmembrane transportKappa-type opioid receptorHomo sapiens (human)
response to acrylamideKappa-type opioid receptorHomo sapiens (human)
positive regulation of eating behaviorKappa-type opioid receptorHomo sapiens (human)
conditioned place preferenceKappa-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayKappa-type opioid receptorHomo sapiens (human)
signal transductionUrotensin-2 receptorHomo sapiens (human)
blood circulationUrotensin-2 receptorHomo sapiens (human)
regulation of blood pressureUrotensin-2 receptorHomo sapiens (human)
blood vessel diameter maintenanceUrotensin-2 receptorHomo sapiens (human)
neuropeptide signaling pathwayUrotensin-2 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (27)

Processvia Protein(s)Taxonomy
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
G-protein alpha-subunit bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled receptor activityMu-type opioid receptorHomo sapiens (human)
beta-endorphin receptor activityMu-type opioid receptorHomo sapiens (human)
voltage-gated calcium channel activityMu-type opioid receptorHomo sapiens (human)
protein bindingMu-type opioid receptorHomo sapiens (human)
morphine receptor activityMu-type opioid receptorHomo sapiens (human)
G-protein beta-subunit bindingMu-type opioid receptorHomo sapiens (human)
neuropeptide bindingMu-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityDelta-type opioid receptorHomo sapiens (human)
protein bindingDelta-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled enkephalin receptor activityDelta-type opioid receptorHomo sapiens (human)
neuropeptide bindingDelta-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor activityKappa-type opioid receptorHomo sapiens (human)
protein bindingKappa-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingKappa-type opioid receptorHomo sapiens (human)
dynorphin receptor activityKappa-type opioid receptorHomo sapiens (human)
neuropeptide bindingKappa-type opioid receptorHomo sapiens (human)
G protein-coupled receptor activityUrotensin-2 receptorHomo sapiens (human)
urotensin II receptor activityUrotensin-2 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (31)

Processvia Protein(s)Taxonomy
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneKappa-type opioid receptorMus musculus (house mouse)
endosomeMu-type opioid receptorHomo sapiens (human)
endoplasmic reticulumMu-type opioid receptorHomo sapiens (human)
Golgi apparatusMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
axonMu-type opioid receptorHomo sapiens (human)
dendriteMu-type opioid receptorHomo sapiens (human)
perikaryonMu-type opioid receptorHomo sapiens (human)
synapseMu-type opioid receptorHomo sapiens (human)
plasma membraneMu-type opioid receptorHomo sapiens (human)
neuron projectionMu-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneDelta-type opioid receptorHomo sapiens (human)
dendrite membraneDelta-type opioid receptorHomo sapiens (human)
presynaptic membraneDelta-type opioid receptorHomo sapiens (human)
axon terminusDelta-type opioid receptorHomo sapiens (human)
spine apparatusDelta-type opioid receptorHomo sapiens (human)
postsynaptic density membraneDelta-type opioid receptorHomo sapiens (human)
neuronal dense core vesicleDelta-type opioid receptorHomo sapiens (human)
plasma membraneDelta-type opioid receptorHomo sapiens (human)
neuron projectionDelta-type opioid receptorHomo sapiens (human)
nucleoplasmKappa-type opioid receptorHomo sapiens (human)
mitochondrionKappa-type opioid receptorHomo sapiens (human)
cytosolKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
membraneKappa-type opioid receptorHomo sapiens (human)
sarcoplasmic reticulumKappa-type opioid receptorHomo sapiens (human)
T-tubuleKappa-type opioid receptorHomo sapiens (human)
dendriteKappa-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneKappa-type opioid receptorHomo sapiens (human)
presynaptic membraneKappa-type opioid receptorHomo sapiens (human)
perikaryonKappa-type opioid receptorHomo sapiens (human)
axon terminusKappa-type opioid receptorHomo sapiens (human)
postsynaptic membraneKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
neuron projectionKappa-type opioid receptorHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
plasma membraneUrotensin-2 receptorHomo sapiens (human)
membraneUrotensin-2 receptorHomo sapiens (human)
plasma membraneUrotensin-2 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (77)

Assay IDTitleYearJournalArticle
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID148279Tested for percentage specific binding of compound at 4.7 nM against [3H]U-69593 on unwashed kappa-opioid receptor binding site1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Isothiocyanate-substituted kappa-selective opioid receptor ligands derived from N-methyl-N-[(1S)-1-phenyl-2-(1-pyrrolidinyl)ethyl] phenylacetamide.
AID331202Displacement of [3H]diprenorphine from human kappa/mu opioid chimera 3 receptor2008Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12
Use of receptor chimeras to identify small molecules with high affinity for the dynorphin A binding domain of the kappa opioid receptor.
AID149749Tested for inhibitory concentration against [3H]DPDPE binding at sites of delta-opioid receptor in guinea pig brain membrane1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Isothiocyanate-substituted kappa-selective opioid receptor ligands derived from N-methyl-N-[(1S)-1-phenyl-2-(1-pyrrolidinyl)ethyl] phenylacetamide.
AID148620Tested for inhibitory concentration against [3H]bremazocine binding to total sites of opioid receptor in guinea pig brain membrane1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Isothiocyanate-substituted kappa-selective opioid receptor ligands derived from N-methyl-N-[(1S)-1-phenyl-2-(1-pyrrolidinyl)ethyl] phenylacetamide.
AID148294Agonist selectivity for kappa opioid receptor in the naltrindole-treated mice. Subcutaneous dose of 12.25 umol/kg of norBNI was administered1994Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26
kappa Opioid receptor selective affinity labels: electrophilic benzeneacetamides as kappa-selective opioid antagonists.
AID180192The compound was evaluated in vivo for sedation in rats by subcutaneous administration using Rotarod assay2000Bioorganic & medicinal chemistry letters, Nov-20, Volume: 10, Issue:22
Arylacetamides as peripherally restricted kappa opioid receptor agonists.
AID135536Molar potency ratio relative to the standard agonist EKC on field-stimulated mouse vas deferens1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
2-(3,4-Dichlorophenyl)-N-methyl-N-[2-(1-pyrrolidinyl)-1-substituted- ethyl]-acetamides: the use of conformational analysis in the development of a novel series of potent opioid kappa agonists.
AID78862Compound was evaluated for In vivo antagonist activity towards guinea pig ileum(GPI)1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
2-(3,4-Dichlorophenyl)-N-methyl-N-[(1S)-1-(3-isothiocyanatophenyl)-2-(1-pyrrolidinyl)ethyl]acetamide: an opioid receptor affinity label that produces selective and long-lasting kappa antagonism in mice.
AID147956Binding affinity against opioid receptor kappa, in guinea pig brain membrane, using [3H]bremazocine as the radioligand.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Structure/activity studies related to 2-(3,4-dichlorophenyl)-N-methyl-N-[2-(1-pyrrolidinyl)-1-substituted- ethyl]acetamides: a novel series of potent and selective kappa-opioid agonists.
AID331198Displacement of [3H]diprenorphine from human kappa opioid receptor expressed in CHO-K1 cells2008Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12
Use of receptor chimeras to identify small molecules with high affinity for the dynorphin A binding domain of the kappa opioid receptor.
AID223113Antinociceptive activity in acetic acid induced abdominal constriction assay after sc administration and abolished by naloxone administered at 3 mg/kg sc in mice1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Structure/activity studies related to 2-(3,4-dichlorophenyl)-N-methyl-N-[2-(1-pyrrolidinyl)-1-substituted- ethyl]acetamides: a novel series of potent and selective kappa-opioid agonists.
AID226718Peripheral restriction index was determined2000Bioorganic & medicinal chemistry letters, Nov-20, Volume: 10, Issue:22
Arylacetamides as peripherally restricted kappa opioid receptor agonists.
AID80129Tested for wash-resistant activity after forty post-washes (for removal of naltrexone) with Kreb's buffer pre-incubated with compound1994Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26
kappa Opioid receptor selective affinity labels: electrophilic benzeneacetamides as kappa-selective opioid antagonists.
AID239438In vitro binding affinity for human kappa opioid receptor was determined by using [3H]diprenorphine as radioligand2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Amino acid conjugates as kappa opioid receptor agonists.
AID132339Compound was evaluated for In vivo antagonist activity towards Mouse vas deferens(MVD)1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
2-(3,4-Dichlorophenyl)-N-methyl-N-[(1S)-1-(3-isothiocyanatophenyl)-2-(1-pyrrolidinyl)ethyl]acetamide: an opioid receptor affinity label that produces selective and long-lasting kappa antagonism in mice.
AID221210Sedative activity after sc administration in female mice (Alderley Park strain)1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Structure/activity studies related to 2-(3,4-dichlorophenyl)-N-methyl-N-[2-(1-pyrrolidinyl)-1-substituted- ethyl]acetamides: a novel series of potent and selective kappa-opioid agonists.
AID77759Agonist potency was determined in electrically stimulated guinea pig ileal longitudinal muscle preparation, pre-incubated with 5 and 20 nM norBNI for 15 min1994Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26
kappa Opioid receptor selective affinity labels: electrophilic benzeneacetamides as kappa-selective opioid antagonists.
AID224426Molar potency ratio relative to the standard agonist EKC assayed in mouse vas deferens.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Structure/activity studies related to 2-(3,4-dichlorophenyl)-N-methyl-N-[2-(1-pyrrolidinyl)-1-substituted- ethyl]acetamides: a novel series of potent and selective kappa-opioid agonists.
AID128825Anti-nociceptive activity (Analgesia reversed by 3 mg/kg of naloxone) after administration through the subcutaneous route to female mice.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
2-(3,4-Dichlorophenyl)-N-methyl-N-[2-(1-pyrrolidinyl)-1-substituted- ethyl]-acetamides: the use of conformational analysis in the development of a novel series of potent opioid kappa agonists.
AID148504Agonist selectivity for delta opioid receptor in the naltrindole-treated mice Subcutaneous dose of 44.44 umol/kg of naltrindole was administered1994Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26
kappa Opioid receptor selective affinity labels: electrophilic benzeneacetamides as kappa-selective opioid antagonists.
AID235140Selectivity was evaluated as ratio of Ki of delta receptor by displacement of [3H]diprenorphine to that of kappa receptor2000Bioorganic & medicinal chemistry letters, Nov-20, Volume: 10, Issue:22
Arylacetamides as peripherally restricted kappa opioid receptor agonists.
AID331201Agonist activity at human kappa opioid receptor transfected in CHO cells by [35S]GTP-gamma-S binding assay2008Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12
Use of receptor chimeras to identify small molecules with high affinity for the dynorphin A binding domain of the kappa opioid receptor.
AID80011Percent recovery of twitch height after 30-40 washes with buffer using smooth guinea pig ileal muscle1996Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8
Arylacetamide-derived fluorescent probes: synthesis, biological evaluation, and direct fluorescent labeling of kappa opioid receptors in mouse microglial cells.
AID149219Ratio of ED50 of compound to delta opioid receptor antagonist naltrindole (NTI) at 44.44 umol/kg administarted sc1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
2-(3,4-Dichlorophenyl)-N-methyl-N-[(1S)-1-(3-isothiocyanatophenyl)-2-(1-pyrrolidinyl)ethyl]acetamide: an opioid receptor affinity label that produces selective and long-lasting kappa antagonism in mice.
AID232278Compound was tested for the nor-BNIb kappa receptors Selectivity of Antinociception in the Mouse Abdominal Stretch Assay by using antagonists; ED50 ratio1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Aspartic acid conjugates of 2-(3,4-dichlorophenyl)-N-methyl-N-[(1S)-1(3-aminophenyl)-2-(1-pyrrolidi nyl) ethyl]acetamide: kappa opioid receptor agonists with limited access to the central nervous system.
AID407193Agonist activity at kappa opioid receptor2008Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles.
AID224414In vitro efficacy against naloxone, in mouse vas deferens, activity expressed as Ke values.1991Journal of medicinal chemistry, Nov, Volume: 34, Issue:11
Structure/activity studies related to 2-(3,4-dichlorophenyl)-N-methyl-N-[2-(1-pyrrolidinyl)-1-substituted- ethyl]acetamides: a novel series of potent and selective kappa-opioid agonists.
AID148567Compound was evaluated for the Opioid receptor kappa 1 affinity using guinea pig brain membranes.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
2-(3,4-Dichlorophenyl)-N-methyl-N-[2-(1-pyrrolidinyl)-1-substituted- ethyl]-acetamides: the use of conformational analysis in the development of a novel series of potent opioid kappa agonists.
AID244190Selectivity of binding affinity of human kappa opioid receptor over human mu opioid receptor2005Bioorganic & medicinal chemistry letters, Mar-01, Volume: 15, Issue:5
Amino acid conjugates as kappa opioid receptor agonists.
AID129488Compound was evaluated for Antinociceptive potencies in mice for in vivo activity in Mouse abdominal stretch assay by icv administration1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Aspartic acid conjugates of 2-(3,4-dichlorophenyl)-N-methyl-N-[(1S)-1(3-aminophenyl)-2-(1-pyrrolidi nyl) ethyl]acetamide: kappa opioid receptor agonists with limited access to the central nervous system.
AID134208Antagonist Ke values of approximately 15 nM which are indicative of k receptor antagonism on field-stimulated mouse vas deferens.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
2-(3,4-Dichlorophenyl)-N-methyl-N-[2-(1-pyrrolidinyl)-1-substituted- ethyl]-acetamides: the use of conformational analysis in the development of a novel series of potent opioid kappa agonists.
AID148278Tested for percentage specific binding of compound at 4.7 nM against [3H]U-69593 on kappa-opioid receptor binding site protected with 1 uM naloxone1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Isothiocyanate-substituted kappa-selective opioid receptor ligands derived from N-methyl-N-[(1S)-1-phenyl-2-(1-pyrrolidinyl)ethyl] phenylacetamide.
AID169274The compound was evaluated in vivo for their ability to inhibit formalin induced financing in rats by subcutaneous administration2000Bioorganic & medicinal chemistry letters, Nov-20, Volume: 10, Issue:22
Arylacetamides as peripherally restricted kappa opioid receptor agonists.
AID78153Compound was tested for their agoinst potencies on the electrically stimulated Guinea pig ileal longitudinal muscle preparation.1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Aspartic acid conjugates of 2-(3,4-dichlorophenyl)-N-methyl-N-[(1S)-1(3-aminophenyl)-2-(1-pyrrolidi nyl) ethyl]acetamide: kappa opioid receptor agonists with limited access to the central nervous system.
AID80136Tested for wash-resistant activity in guinea pig ileal longitudinal muscle preparation, after forty washes with Kreb's buffer pre-incubated with compound1994Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26
kappa Opioid receptor selective affinity labels: electrophilic benzeneacetamides as kappa-selective opioid antagonists.
AID235141Selectivity was evaluated as ratio of Ki of mu receptor by displacement of [3H]diprenorphine to that of kappa receptor2000Bioorganic & medicinal chemistry letters, Nov-20, Volume: 10, Issue:22
Arylacetamides as peripherally restricted kappa opioid receptor agonists.
AID407192Binding affinity to human urotensin-2 receptor2008Bioorganic & medicinal chemistry letters, Jul-01, Volume: 18, Issue:13
Potent and selective small-molecule human urotensin-II antagonists with improved pharmacokinetic profiles.
AID553072Potency index, ratio of antinociceptive ED50 in icv dosed HSD:ICR(CD1) mouse to antinociceptive ED50 in intrathecally dosed HSD:ICR(CD1) mouse2011ACS medicinal chemistry letters, Jan-13, Volume: 2, Issue:1
A κ Opioid Pharmacophore Becomes a Spinally Selective κ-δ Agonist When Modified with a Basic Extender Arm.
AID129605Compound was evaluated for Antinociceptive Potency by using mouse abdominal stretch assay after sc administration1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
2-(3,4-Dichlorophenyl)-N-methyl-N-[(1S)-1-(3-isothiocyanatophenyl)-2-(1-pyrrolidinyl)ethyl]acetamide: an opioid receptor affinity label that produces selective and long-lasting kappa antagonism in mice.
AID148306Inhibitory activity against Opioid receptor kappa 1 in electrically stimulated mouse vas deferens (MVD) preparation.1996Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8
Arylacetamide-derived fluorescent probes: synthesis, biological evaluation, and direct fluorescent labeling of kappa opioid receptors in mouse microglial cells.
AID169273The compound was evaluated in vivo for its ability to inhibit formalin induced flinching in rats by intrapaw administration2000Bioorganic & medicinal chemistry letters, Nov-20, Volume: 10, Issue:22
Arylacetamides as peripherally restricted kappa opioid receptor agonists.
AID80133Tested for wash-resistant activity by incubating guinea pig ileal longitudinal muscle (pre-treated with the compound) with nor BNI (20 nM). Number of determinations, n=31994Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26
kappa Opioid receptor selective affinity labels: electrophilic benzeneacetamides as kappa-selective opioid antagonists.
AID241920Inhibition of cytochrome P450 2D6 was determined using MAMC (7-methoxy-4-aminomethyl-coumarin) as substrate2005Bioorganic & medicinal chemistry letters, May-16, Volume: 15, Issue:10
Arylacetamide kappa opioid receptor agonists with reduced cytochrome P450 2D6 inhibitory activity.
AID148831Agonist potency of compound was evaluated towards kappa opioid receptor in absence of antagonist in guinea pig ileum(GPI)1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
2-(3,4-Dichlorophenyl)-N-methyl-N-[(1S)-1-(3-isothiocyanatophenyl)-2-(1-pyrrolidinyl)ethyl]acetamide: an opioid receptor affinity label that produces selective and long-lasting kappa antagonism in mice.
AID553070Antinociceptive activity in icv dosed HSD:ICR(CD1) mouse by tail flick test2011ACS medicinal chemistry letters, Jan-13, Volume: 2, Issue:1
A κ Opioid Pharmacophore Becomes a Spinally Selective κ-δ Agonist When Modified with a Basic Extender Arm.
AID148691Tested for inhibitory concentration against [3H]U-69593 binding at sites of kappa-opioid receptor in guinea pig brain membrane1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Isothiocyanate-substituted kappa-selective opioid receptor ligands derived from N-methyl-N-[(1S)-1-phenyl-2-(1-pyrrolidinyl)ethyl] phenylacetamide.
AID141634Ratio of ED50 of compound to mu opioid receptor antagonist beta-funaltrexamine (FMN) at 10.18 umol/kg administarted sc1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
2-(3,4-Dichlorophenyl)-N-methyl-N-[(1S)-1-(3-isothiocyanatophenyl)-2-(1-pyrrolidinyl)ethyl]acetamide: an opioid receptor affinity label that produces selective and long-lasting kappa antagonism in mice.
AID135326BBB penetration classification2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
AID238876Inhibitory constant against human Opioid receptor kappa using [3H]diprenorphine as radio ligand2005Bioorganic & medicinal chemistry letters, May-16, Volume: 15, Issue:10
Arylacetamide kappa opioid receptor agonists with reduced cytochrome P450 2D6 inhibitory activity.
AID148280Tested for percentage specific binding of compound at 4.7 nM against [3H]U-69593 on washed kappa-opioid receptor binding site1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Isothiocyanate-substituted kappa-selective opioid receptor ligands derived from N-methyl-N-[(1S)-1-phenyl-2-(1-pyrrolidinyl)ethyl] phenylacetamide.
AID238871Inhibitory constant against human Opioid receptor mu 1 using [3H]diprenorphine as radio ligand2005Bioorganic & medicinal chemistry letters, May-16, Volume: 15, Issue:10
Arylacetamide kappa opioid receptor agonists with reduced cytochrome P450 2D6 inhibitory activity.
AID131750Tested for antinociceptive potency by Mouse abdominal stretch assay1994Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26
kappa Opioid receptor selective affinity labels: electrophilic benzeneacetamides as kappa-selective opioid antagonists.
AID141489Tested for inhibitory concentration against [3H]DAMGO binding at sites of mu-opioid receptor in guinea pig brain membrane1994Journal of medicinal chemistry, Sep-02, Volume: 37, Issue:18
Isothiocyanate-substituted kappa-selective opioid receptor ligands derived from N-methyl-N-[(1S)-1-phenyl-2-(1-pyrrolidinyl)ethyl] phenylacetamide.
AID553071Antinociceptive activity in intrathecally dosed HSD:ICR(CD1) mouse by tail flick test2011ACS medicinal chemistry letters, Jan-13, Volume: 2, Issue:1
A κ Opioid Pharmacophore Becomes a Spinally Selective κ-δ Agonist When Modified with a Basic Extender Arm.
AID232273Compound was tested for the NTI Delta receptor Selectivity of Antinociception in the Mouse Abdominal Stretch Assay by using antagonists; ED50 ratio1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Aspartic acid conjugates of 2-(3,4-dichlorophenyl)-N-methyl-N-[(1S)-1(3-aminophenyl)-2-(1-pyrrolidi nyl) ethyl]acetamide: kappa opioid receptor agonists with limited access to the central nervous system.
AID80010Percent recovery after treatment with 500 nM of NTX and removal of NTX by 40 washes with buffer using smooth guinea pig ileal muscle1996Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8
Arylacetamide-derived fluorescent probes: synthesis, biological evaluation, and direct fluorescent labeling of kappa opioid receptors in mouse microglial cells.
AID148022In vitro binding affinity towards Opioid receptor kappa 1 by displacement of bound [3H]U-695932000Bioorganic & medicinal chemistry letters, Nov-20, Volume: 10, Issue:22
Arylacetamides as peripherally restricted kappa opioid receptor agonists.
AID129485Compound was evaluated for Antinociceptive potencies in mice for in vivo activity Mouse abdominal stretch assay by iv administration1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Aspartic acid conjugates of 2-(3,4-dichlorophenyl)-N-methyl-N-[(1S)-1(3-aminophenyl)-2-(1-pyrrolidi nyl) ethyl]acetamide: kappa opioid receptor agonists with limited access to the central nervous system.
AID240265Agonist activity assessed by ability to stimulate [35S]GTP gammaS binding to opioid receptor kappa in human membranes2005Bioorganic & medicinal chemistry letters, May-16, Volume: 15, Issue:10
Arylacetamide kappa opioid receptor agonists with reduced cytochrome P450 2D6 inhibitory activity.
AID76374Tested for agonist potency by conducting tests on electrically stimulated guinea pig ileal longitudinal muscle preparation1994Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26
kappa Opioid receptor selective affinity labels: electrophilic benzeneacetamides as kappa-selective opioid antagonists.
AID238911Inhibitory constant against human Opioid receptor delta 1 using [3H]diprenorphine as radio ligand2005Bioorganic & medicinal chemistry letters, May-16, Volume: 15, Issue:10
Arylacetamide kappa opioid receptor agonists with reduced cytochrome P450 2D6 inhibitory activity.
AID148425Ratio of ED50 of compound to kappa opioid receptor antagonist norbinaltorphimine (nor-BNI) at conc. of 12.25 umol/kg administarted sc1994Journal of medicinal chemistry, May-27, Volume: 37, Issue:11
2-(3,4-Dichlorophenyl)-N-methyl-N-[(1S)-1-(3-isothiocyanatophenyl)-2-(1-pyrrolidinyl)ethyl]acetamide: an opioid receptor affinity label that produces selective and long-lasting kappa antagonism in mice.
AID132848Tested for agonist potency by conducting tests on mouse vas deferens preparation1994Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26
kappa Opioid receptor selective affinity labels: electrophilic benzeneacetamides as kappa-selective opioid antagonists.
AID232275Compound was tested for the beta-FNA Mu receptors Selectivity of Antinociception in the Mouse Abdominal Stretch Assay by using antagonists; ED50 ratio1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Aspartic acid conjugates of 2-(3,4-dichlorophenyl)-N-methyl-N-[(1S)-1(3-aminophenyl)-2-(1-pyrrolidi nyl) ethyl]acetamide: kappa opioid receptor agonists with limited access to the central nervous system.
AID132504Compound was tested for its agoinst potencies on the electrically stimulated mouse vas deferens1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Aspartic acid conjugates of 2-(3,4-dichlorophenyl)-N-methyl-N-[(1S)-1(3-aminophenyl)-2-(1-pyrrolidi nyl) ethyl]acetamide: kappa opioid receptor agonists with limited access to the central nervous system.
AID331199Displacement of [3H]diprenorphine from human mu opioid receptor expressed in CHO-K1 cells2008Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12
Use of receptor chimeras to identify small molecules with high affinity for the dynorphin A binding domain of the kappa opioid receptor.
AID148686Inhibitory activity against Opioid receptor kappa 1 in electrically stimulated guinea pig longitudinal ileal muscle (GPI) preparation.1996Journal of medicinal chemistry, Apr-12, Volume: 39, Issue:8
Arylacetamide-derived fluorescent probes: synthesis, biological evaluation, and direct fluorescent labeling of kappa opioid receptors in mouse microglial cells.
AID80130Tested for wash-resistant activity after forty post-washes (for removal of nor BNI) with Kreb's buffer pre-incubated with compound1994Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26
kappa Opioid receptor selective affinity labels: electrophilic benzeneacetamides as kappa-selective opioid antagonists.
AID331200Displacement of [3H]diprenorphine from human delta opioid receptor expressed in CHO-K1 cells2008Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12
Use of receptor chimeras to identify small molecules with high affinity for the dynorphin A binding domain of the kappa opioid receptor.
AID331203Displacement of [3H]diprenorphine from human kappa/mu opioid chimera 4 receptor2008Bioorganic & medicinal chemistry letters, Jun-15, Volume: 18, Issue:12
Use of receptor chimeras to identify small molecules with high affinity for the dynorphin A binding domain of the kappa opioid receptor.
AID80131Tested for wash-resistant activity by incubating guinea pig ileal longitudinal muscle (pre-treated with the compound) with naltrexone (500 nM). Number of determinations, n=31994Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26
kappa Opioid receptor selective affinity labels: electrophilic benzeneacetamides as kappa-selective opioid antagonists.
AID141626Agonist selectivity for mu opioid receptor in the beta-funaltrexamine-treated mice Subcutaneous dose of 20.36 umol/kg of beta-FNA was administered1994Journal of medicinal chemistry, Dec-23, Volume: 37, Issue:26
kappa Opioid receptor selective affinity labels: electrophilic benzeneacetamides as kappa-selective opioid antagonists.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (30)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (3.33)18.7374
1990's7 (23.33)18.2507
2000's16 (53.33)29.6817
2010's3 (10.00)24.3611
2020's3 (10.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.18

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.18 (24.57)
Research Supply Index2.83 (2.92)
Research Growth Index5.01 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.18)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other16 (100.00%)84.16%
Other16 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]